TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
2.1.2.1 Key data from primary sources 26
2.1.2.2 Key industry insights 27
2.2 MARKET SIZE ESTIMATION 28
2.2.1 BOTTOM-UP APPROACH 29
2.2.2 TOP-DOWN APPROACH 29
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 30
2.4 MARKET SHARE ESTIMATION 31
2.5 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 CRO SERVICES MARKET OVERVIEW 35
4.2 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE AND COUNTRY 36
4.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37
4.4 CRO SERVICES MARKET: GEOGRAPHIC MIX 38
4.5 CRO SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 Growing R&D expenditure 41
5.2.1.2 Increased outsourcing of R&D activities 42
5.2.1.3 Increasing number of clinical trials 43
5.2.2 OPPORTUNITIES 44
5.2.2.1 Growth in the biosimilars and biologics markets 44
5.2.2.2 Rising demand for specialized testing services 45
5.2.2.3 Emerging Asian markets 46
5.2.3 CHALLENGES 47
5.2.3.1 Intense competition in the cro services market 47
5.2.3.2 Shortage of skilled professionals 47
5.3 INDUSTRY TRENDS 48
5.3.1 GROWING CONSOLIDATION IN THE CRO INDUSTRY 48
5.3.2 INCREASING OUTSOURCING OF CLINICAL TRIALS TO EMERGING MARKETS 50
5.3.3 ADOPTION OF NEW TECHNOLOGIES 51
6 CRO SERVICES MARKET, BY TYPE 52
6.1 INTRODUCTION 53
6.2 CLINICAL RESEARCH SERVICES 54
6.2.1 PHASE I CLINICAL RESEARCH SERVICES 57
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 59
6.2.3 PHASE III CLINICAL RESEARCH SERVICES 60
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 62
6.3 EARLY-PHASE DEVELOPMENT SERVICES 63
6.3.1 DISCOVERY STUDIES 66
6.3.2 CHEMISTRY, MANUFACTURING, & CONTROL (CMC) 67
6.3.3 PRECLINICAL SERVICES 68
6.3.3.1 Pharmacokinetics/pharmacodynamics (PK/PD) 70
6.3.3.2 Toxicology testing services 71
6.3.3.3 Other preclinical services 72
6.4 LABORATORY SERVICES 73
6.4.1 BIOANALYTICAL TESTING SERVICES 75
6.4.2 ANALYTICAL TESTING SERVICES 76
6.4.2.1 Physical characterization 77
6.4.2.2 Raw material testing 78
6.4.2.3 Batch-release testing 79
6.4.2.4 Stability testing 80
6.4.2.5 Other analytical testing services 82
6.5 CONSULTING SERVICES 82
7 GLOBAL CRO SERVICES MARKET, BY THERAPEUTIC AREA 85
7.1 INTRODUCTION 86
7.2 ONCOLOGY 87
7.3 INFECTIOUS DISEASES 90
7.4 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 92
7.5 IMMUNOLOGICAL DISORDERS 94
7.6 CARDIOVASCULAR DISEASES 96
7.7 RESPIRATORY DISORDERS 99
7.8 DIABETES 100
7.9 OTHER THERAPEUTIC AREAS 102
8 CRO SERVICES MARKET, BY END USER 104
8.1 INTRODUCTION 105
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 106
8.3 MEDICAL DEVICE COMPANIES 108
8.4 ACADEMIC INSTITUTES 109
9 CRO SERVICES MARKET, BY REGION 111
9.1 INTRODUCTION 112
9.2 NORTH AMERICA 113
9.2.1 US 118
9.2.2 CANADA 123
9.3 EUROPE 127
9.3.1 GERMANY 133
9.3.2 UK 137
9.3.3 FRANCE 141
9.3.4 ITALY 145
9.3.5 SPAIN 149
9.3.6 REST OF EUROPE 153
9.4 ASIA PACIFIC 157
9.4.1 CHINA 163
9.4.2 JAPAN 168
9.4.3 INDIA 171
9.4.4 REST OF ASIA PACIFIC 176
9.5 LATIN AMERICA 181
9.6 MIDDLE EAST & AFRICA 185
10 COMPETITIVE LANDSCAPE 190
10.1 OVERVIEW 190
10.2 MARKET SHARE ANALYSIS 191
10.3 COMPETITIVE SCENARIO 195
10.3.1 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS (2014-2017) 195
10.3.2 SERVICE LAUNCHES (2014-2017) 195
10.3.3 EXPANSIONS (2014-2017) 196
10.3.4 ACQUISITIONS (2014-2017) 196
 
11 COMPANY PROFILES 197
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
11.1 IQVIA 197
11.2 LABCORP 202
11.3 PAREXEL 207
11.4 PRA HEALTH SCIENCES 212
11.5 PPD 216
11.6 ICON PLC 220
11.7 SYNEOS HEALTH 225
11.8 WUXI PHARMATECH 230
11.9 CHARLES RIVER 234
11.10 MEDPACE HOLDINGS 238
11.11 SGS 241
11.12 ENVIGO 246
11.13 MPI RESEARCH 247
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
12 APPENDIX 249
12.1 INSIGHTS OF INDUSTRY EXPERTS 249
12.2 DISCUSSION GUIDE 250
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 254
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 256
12.5 AVAILABLE CUSTOMIZATIONS 258
12.6 RELATED REPORTS 259
12.7 AUTHOR DETAILS 260